Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 117 ADC-related abstracts that have been carefully screened and added to the Beacon database. Of these 117 abstracts, 115 (98%) presented studies that investigate ADCs in the clinic for the first approval, and the remaining two were investigated in the preclinical setting.
Almost half of the abstracts, 47% (55/117), focus on approved ADC drugs with KADCYLA® and ENHERTU® being the most discussed approved ADCs at ASCO 2022.
For more insight please download the sample, contact us, or request a demo.
Find out more
This insight and data is part of the subscription to Beacon ADC.
Speak with our expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your ADC questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements